Celldex shares are trading lower. The company reported topline results from the Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria whose symptoms are inadequately controlled by H1-antihistamines.